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tinuclear antibodies and rheumatoid factor, were negative,
and levels of angiotensin-converting enzyme were nega-
tive. Tests for antibodies against the human immunodefi-
ciency virus (HIV) and for HIV p24 antigen were nega-
tive, and the erythrocyte sedimentation rate was 53 mm
per hour. The patient was treated intravenously with phen-
ytoin and high-dose penicillin G for 21 days. Magnetic res-
onance imaging of the brain six days after the initiation of
therapy showed no enhancement of the left frontal lesion,
and one month later the abnormal signal had disappeared
(Fig. 1B). Studies of cerebrospinal fluid six months after
the completion of therapy were normal, with a nonreactive
VDRL test.
The findings of abnormalities on magnetic resonance
imaging and a reactive VDRL test of cerebrospinal fluid,
along with a therapeutic response to intravenous penicil-
lin, made the diagnosis of neurosyphilis almost certain in
our patient.2 The incidence of neurosyphilis has increased
over the past two decades, particularly in immunocompro-
mised hosts.3,4 In patients presenting with focal motor sta-
tus epilepticus and corresponding abnormally enhancing
lesions on magnetic resonance imaging of the brain, the
diagnosis of neurosyphilis should be seriously considered
regardless of their immune status. The response to treat-
ment should be evaluated by follow-up radiologic and cer-
ebrospinal fluid studies.
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Antiplatelet and Anticoagulant Therapy
after Coronary-Artery Stenting
To the Editor: Schömig et al. (April 25 issue)1 report that
they did not observe neutropenia in any of the 257 pa-
tients receiving short-term ticlopidine therapy after coro-
nary stenting. The authors note that in the literature, all
reported cases of neutropenia were fully reversible and had
developed in the second and third month of long-term
therapy with ticlopidine. For these reasons, Schömig et al.
consider the possible side effect of neutropenia with short-
term ticlopidine therapy to be of little clinical importance.
We do not agree with this view because of our clinical ex-
perience and other reports in the Journal 2 not mentioned
by Schömig et al. 
We observed severe neutropenia (84 neutrophils per cu-
bic millimeter) in a 79-year-old man 23 days after the ini-
tiation of ticlopidine therapy because of coronary-artery
stenting. Blood counts had been performed every third
day after stenting, and the total white-cell count declined
on the 20th day.
The medical literature reports that agranulocytosis may
occur as early as 15 or 27 days after the start of ticlopidine
therapy, may not always be reversible, and in rare cases may
be fatal.2 The manufacturer recommends blood-count
monitoring every other week for the first three months of
ticlopidine therapy. In their study, Schömig et al. per-
formed blood counts in their patients only during the first
10 days. Thus, most of their patients received ticlopidine
over an ensuing period of at least 18 days without blood
counts. Apparently, this approach caused no harm to their
patients. However, we suggest that during short-term
ticlopidine therapy, blood counts be performed at least ev-
ery other week or if symptoms develop — particularly with
signs of infection.
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To the Editor: Schömig et al. conclude that “as compared
with conventional anticoagulant therapy, combined anti-
platelet therapy after the placement of coronary-artery
stents reduces the incidence of both cardiac events and
hemorrhagic and vascular complications.” Some aspects of
the study need to be clarified before these conclusions are
generally applied to patients who undergo coronary-artery
stenting.
The main indications for stenting in the study were
“extensive coronary-artery dissection after PTCA [percu-
taneous transluminal coronary angioplasty], complete
vessel closure, [and] residual stenosis of 30 percent or
more.” These conditions are associated with an increased
risk of acute or subacute stent thrombosis.1 The authors
state that “all patients in whom stenting was successful
(i.e., in whom the stent was placed at the desired position
and there was less than 30 percent residual stenosis)”
were eligible for randomization. Excluded from the study
were “patients in whom stenting was intended primarily
as a bridge to aortocoronary bypass grafting, who had
cardiogenic shock, or who had needed mechanical venti-
lation before undergoing PTCA.” The number of pa-
tients excluded was very high. A total of 517 patients
were eligible and consented to be randomized, and 109
patients were excluded (17.4 percent). Also, the mean
percentage of residual stenosis after stenting in the en-
rolled patients was less than 3 percent, a value indicating
the successful placement of stents in the enrolled pa-
tients. These data suggest that only patients with excel-
lent results after coronary stenting were included, and a
substantial number of patients with a high risk of throm-
botic occlusion of the stent were excluded before ran-
domization. It would be interesting to know the specific
causes of exclusion and the in-hospital course of the ex-
cluded patients.
In addition, the authors report the dissection rate be-
fore coronary stenting but not the incidence of residual
dissection after placement of the stent. How many patients
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had coronary dissection after stenting in the two random-
ized groups? Residual dissection after intracoronary-stent
implantation is an important predictor of subacute stent
thrombosis.1 Different outcomes in the two randomized
groups could be explained by different rates of residual
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The authors reply:
To the Editor: Schöneberger and Schmidt and Cequier
and colleagues raise important questions about the gen-
eralizability of our findings to the large number of pa-
tients who undergo coronary-stent implantation. Cequier
and colleagues are concerned that we might have prefer-
entially excluded high-risk patients. Among the 626 con-
secutive patients undergoing stent implantation on our
service during the study period, the most frequent reason
for ineligibility was the patient’s refusal to participate in
the study, which accounted for 9.9 percent of the pa-
tients. Other reasons for ineligibility were procedural fail-
ure in 3.7 percent of the patients, cardiogenic shock or
the need for mechanical ventilation due to acute myocar-
dial infarction before the intervention in 2.7 percent, an
absolute indication for anticoagulation therapy in 0.6
percent, and the use of a stent as a bridge to bypass graft-
ing in 0.5 percent. In none of the patients was residual
dissection after stenting a reason for exclusion. The fre-
quency of a major residual dissection after stenting was
1.5 percent in the entire study group, and the frequency
did not differ significantly between the two treatment
groups. 
We do not consider our patient population a low-risk
cohort, because 59 percent of the target lesions were clas-
sified as type C. Moreover, 24 percent of our patients pre-
sented with acute myocardial infarction, and 45 percent
with unstable angina. Subgroup analysis shows that pa-
tients at high risk for stent occlusion, such as those with
acute myocardial infarction,1 benefit the most from com-
bined antiplatelet therapy.
Drs. Schöneberger and Schmidt point out that severe
neutropenia can develop as soon as 15 days after treatment
with ticlopidine. However, at such an early stage, neutro-
penia appears to be exceedingly rare. In 1529 patients who
took part in the largest trial of ticlopidine,2 neutropenia
did not occur during the first month. Blood-count moni-
toring after discharge from the hospital was not part of our
study protocol and was left to the discretion of the pa-
tients’ physicians, who carried on with the treatment after
discharge. We believe that blood counts should be per-
formed during the third and fourth week of treatment.
Most important, continuation of ticlopidine therapy after
four weeks should be strictly avoided. With such surveil-
lance, the risk of neutropenia can be minimized and thus
should not limit the administration of combined antiplate-
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Aspirin and Coronary Disease
To the Editor: In his editorial on platelets and coronary
artery disease (April 25 issue),1 Handin states, “Aspirin has
now become an essential cardiovascular drug, and it is un-
usual to find patients with established coronary artery dis-
ease who do not take it.” Sadly, despite overwhelming ev-
idence of the clinical benefit of aspirin in patients with
coronary heart disease, many if not most patients with es-
tablished disease do not take aspirin. Only 37 percent of
patients received aspirin in the Scandinavian Simvastatin
Survival Study.2 Reviewing the treatment of Medicare pa-
tients with acute myocardial infarction, the Cooperative
Cardiovascular Project found that only 50 percent of pa-
tients received aspirin within 48 hours after the diagnosis
of infarction.3 Moreover, the mortality rate at six months
among patients not receiving aspirin was twice the rate
among those receiving it.4 Studying community practice,
Shahar et al. found a low level of aspirin use among pa-
tients with symptomatic coronary heart disease: 58 per-
cent among white men, 35 percent among black men,
34 percent among white women, and 13 percent among
black women.5 Physicians’ misperceptions of the available
data are a substantial problem. Ayanian et al. found that
only 55 percent of internists believe that aspirin definitely
improves the long-term prognosis after myocardial infarc-
tion.6 
Documentation of similar deficiencies in care abounds
in medicine. The reasons for not prescribing effective ther-
apies are complex and may involve cost considerations. In
the case of aspirin, high cost is not a factor.
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